Kate MacQueen, PhD, MPHSenior Scientist, Social and Behavioral Health Sciences
Areas of expertise
- Social, behavioral and ethical aspects of biomedical HIV prevention trials
- Community-based participatory research
- Stakeholder engagement
- Mixed methods research
- Gender dynamics
Projects & Resources
The Building Healthy Communities project is focused on building evidence that integrated, multisector efforts to improve community health are more effective than nonintegrated approaches.
FHI 360 developed and introduced innovative HIV prevention technologies — including microbicides and antiretrovirals — and worked with local partners to address the need for HIV prevention options, particularly for women.
This manual provides research staff of HIV prevention clinical trials with strategies to support adherence to the use of antiretroviral-based vaginal rings and potentially other HIV prevention products.
Published Research/** * @file * Unformatted override for published research. * Using the same markup as "project" because it's the same */ ?>
Developing a framework for evaluating ethical outcomes of good participatory practices in TB clinical drug trials
MacQueen KM, Eley NT, Frick M, Mingote LR, Chou A, Seidel SS, Hannah S, Hamilton C
J Empir Res Hum Res Ethics 2016 Jul; 11(3): 203-13. [Journal Impact Factor: 1.146]
With the growing acceptance of community engagement and participatory strategies in clinical research, evaluation of the benefits and burdens are needed. Working with global tuberculosis (TB) stakeholders, the authors developed a theory of change evaluation framework for the Good Participatory Practice Guidelines for TB Drug Trials. The framework is a first step in systematically evaluating participatory research in clinical trials.
Biomarkers and biometric measures of adherence to use of ARV-based vaginal rings
Stalter RM, Moench TR, MacQueen KM, Tolley EE, Owen DH, Consortium for Ring Adherence
J Int AIDS Soc 2016 May; 19 (1): 20746. [Journal Impact Factor: 5.090]
Poor adherence has been observed in trials of HIV prevention products containing antiretroviral-based oral and vaginal gel, resulting in an inability to determine product efficacy. This landscape analysis was conducted to identify potential technologies for objective product adherence measurement in antiretroviral-based HIV prevention trials to accurately determine efficacy. The authors recommend a strategy of using complementary biometric and behavioral approaches to best understand participants' adherence to antiretroviral-based vaginal rings in clinical trials.
Socioeconomic and behavioral factors influencing choice, adherence and success of microbicide formulations
Tolley E, Friedland B, Gafos M, Amico R, Van Damme L, Woodsong C, MacQueen K, Mansoor L, McCormack S
In: das Neves, Jose, Sarmento, Bruno, editors. Drug delivery and development of anti-HIV microbicides. Singapore: Pan Stanford Publishing; 2015. pp. 569-654. [Journal Impact Factor: n/a]
High product adherence is critical to the success of HIV prevention trials and the public health impact of products available in clinics. Some adherence determinants in these two contexts differ. This chapter presents a conceptual framework and draws widely on published and unpublished data to discuss the socioeconomic and behavioral factors influencing choice, adherence and success of different microbicide formulations.